Mylan launches generic bipolar disorder, allergy treatments

Generic versions of Lithobid, Clarinex launched

PITTSBURGH — Mylan has launched generic versions of two drugs to treat bipolar disorder and allergies, the company said Tuesday.

Mylan announced the launch of lithium carbonate extended-release tablets in the 300-mg strength. The drug is a generic version of Noven Therapeutics' Lithobid, various versions of which had sales of about $21 million during the 12-month period ended in March, according to IMS Health.

The company also launched desloratadine tablets in the 5-mg strength, a generic version of allergy treatment Clarinex, made by Schering-Plough, now part of Merck. Various versions of the drug had sales of about $194.6 million during the 12-month period that ended in March.

Mylan said it would ship both products immediately.

Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

Login or Register to post a comment.